Is Abvc Biopharma going out of business?

ABVC BIOPHARMA, INC. (ABVC) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ABVC BIOPHARMA, INC. (ABVC) scores 9 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 59.14% (YoY)

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $94.4K of cash and short-term investments against $12.4M of annual burn. Adjusted shares outstanding increased 59.1% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-13.2% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 5 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 59.14% (YoY)
• ROIC: -57.98%
• Interest coverage: -638.0x
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -32.67%
• Debt / Equity: No financial debt (debt-free)
• Return on Assets: -40.76%
• R&D intensity: 28.95%
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)
• Price / Earnings: Unprofitable (see Valuation)
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-27.

Price as of 2026-09-26.